32.97
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st
What drives Supernus Pharmaceuticals Inc. stock priceFastest return on investment - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Quiver Quantitative
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - Yahoo.co
What analysts say about Supernus Pharmaceuticals Inc. stockTremendous portfolio expansion - jammulinksnews.com
Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox
(SUPN) Investment Report - news.stocktradersdaily.com
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance
Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World
Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
When the Price of (SUPN) Talks, People Listen - news.stocktradersdaily.com
Supernus Pharmaceuticals to Acquire Sage Therapeutics in Transaction Valued Up to $795 Million - Global Legal Chronicle
Busy Philipps, Jay Glazer highlight ADHD experiences in Supernus’ campaigns - Medical Marketing and Media
Sage Therapeutics cuts over 300 jobs after securing buyer - The Business Journals
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK
Supernus to acquire depression drugmaker Sage - MSN
Apomorphine Delivery Device Market Set to Witness Significant - openPR.com
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360
Deals of the day-Mergers and acquisitions - marketscreener.com
Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa
Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):